Silent Myocardial Ischemia
9
1
2
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
11.1%
1 terminated out of 9 trials
80.0%
-6.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (9)
INsTantenous wavE-Free Ratio-guided PCI Versus Fractional Flow REserve-Guided PCI in rouTine Clinical Practice, Prospective, Multicenter Registry
Silent Myocardial Ischemia in Patients Undergoing Non-oncological Abdominal Surgeries
Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization.
Heterogeneity of Neointimal Healing Following Biodegradable-polymer Drug-Eluting Coronary Stent Implantation
Detection no Invasive of a Silent Myocardial Ischemia
Early Detection of Silent Myocardial Ischemia
Does Ranolazine Decrease Biomarkers of Myocardial Damage in Diabetics
BuMA OCT Study(A Comparative Evaluation of the Extent of Neointima Formation at 3 Months After Implantation Using OCT)
Prospective Study to Assess DES Re-endothelization in BMS Restenosis and De-novo Lesions